Happy Holidays. Keep checking for new content.

Active Surveillance for Prostate Cancer: How to Do It Right

by Jim Barney on July 2, 2017

Share

Active surveillance should be offered to patients with a low risk of cancer progression, including those with a life expectancy of more than 10 years, clinical stage T1/2a disease, a PSA level < 15 ng/mL, and biopsy Gleason score of ≤ 6. Read the article here.

{ 0 comments… add one now }

Previous post:

Next post: